TauRx from the Sun (UK) Trial results suggest HMTM has a better safety profile than other treatments, with fewer adverse side effects.
However, experts are divided on the drug's effectiveness, with concerns about unpublished and non-peer-reviewed clinical trial data.
A source close to the regulatory process claimed TauRX had provided limited evidence beyond the drug's effects of "making your urine turn green and your poo turn blue".
The source added that the company's case was "very difficult to understand" and appeared to be "trying to be complicated and confusing".
The company has reportedly refused to accept previous trial results showing the drug performed no better than placebo.
This raises the possibility of HMTM becoming the third consecutive Alzheimer's treatment to face NHS rejection.
At the Alzheimer's Disease International conference in 2024, trial results showed no overall benefit over placebo on memory and cognitive decline, which the company attributed to unexpected placebo effects.
Dr Richard Oakley from Alzheimer's Society noted that in a small subset of participants with mild cognitive impairment, HMTM showed beneficial effects.
LINK